Kurse | Charts | Stammdaten | Kennzahlen | Aktion |
---|---|---|---|---|
Snapshot | Preischart | Daten + Gebühr | Performance | Portfolio |
Börsenplätze | Performance | Management | Volatilität | Watchlist |
Historisch | Benchmark | Dokumente | Sharpe Ratio | |
Rendite | Ratings |
Kurse
Charts
Stammdaten
Kennzahlen
Anlageziel Select Investment Series III SICAV - T. Rowe Price Health Science Equity Fund Q Fonds
To increase the value of its shares, over the long term, through growth in the value of, and income from, its investments. The fund is actively managed and invests mainly in a diversified portfolio of shares of companies that are involved in the research, development, production, or distribution of products or services related to health sciences. The companies may be anywhere in the world, including emerging markets, with a focus on companies in the United States.
Stammdaten
Valor | 113766580 |
ISIN | LU2349435961 |
Fondsgesellschaft | T. Rowe Price Management |
Kategorie | Branchen: Gesundheitswesen |
Währung | USD |
Mindestanlage | 881.00 |
VL-fähig? | Nein |
Thesaurierend/Ausschüttend | Thesaurierend |
Fondsmanager | Ziad Bakri |
Aktuelle Daten
Fondsnote | - |
Aktueller Rücknahmepreis | 8.87 |
Fonds Volumen | 232’566’430.66USD |
Total Expense Ratio (TER) | 0.96% |
Gebühren
Verwaltungsgebühr | - |
Depotbankgebühr | - |
Rücknahmegebühr | - |
Ausgabeaufschlag | - |
Basisdaten
Auflagedatum | 08.11.2021 |
Depotbank | J.P. Morgan SE, Luxembourg Branch |
Zahlstelle | |
Domizil | Luxembourg |
Geschäftsjahr | 31.12.2024 |
Performancedaten
Veränderung Vortag | 0.04 USD (0.45 %) |